Forty strains of Helicobacter pylori had an MIC50 of 4 mg/L of the non-absorbably antibiotic, rifaximin. Neither synergy nor antagonism was demonstrated when the drug was combined with ampicillin, metronidazole and omeprazole and the rate of spontaneous mutation was less than 1 in 102. With these in-vitro characteristics, rifaximin should now be assessed for clinical efficacy. © 1995 The British Society for Antimicrobial Chemotherapy.
Holton J., Vaira D., Menegatti M., Barbara L. (1995). The susceptibility of helicobacter pylori to the rifamycin, rifaximin. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 35(4), 545-549 [10.1093/jac/35.4.545].
The susceptibility of helicobacter pylori to the rifamycin, rifaximin
Vaira D.;Barbara L.
1995
Abstract
Forty strains of Helicobacter pylori had an MIC50 of 4 mg/L of the non-absorbably antibiotic, rifaximin. Neither synergy nor antagonism was demonstrated when the drug was combined with ampicillin, metronidazole and omeprazole and the rate of spontaneous mutation was less than 1 in 102. With these in-vitro characteristics, rifaximin should now be assessed for clinical efficacy. © 1995 The British Society for Antimicrobial Chemotherapy.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
